Abstract:Abstract Triple Negative Breast Cancer (TNBC) affects approximately 15-20% of BC patients, yet accounts for a disproportionately higher rate of BC morbidity and mortality, in part due to lack of targeted therapies. We have shown that estrogen receptor beta (ERβ) is expressed in approximately 20% of TN breast tumors and that ligand-mediated activation of ERβ with estradiol (E2) or ERβ-selective agonists decreases tumor cell proliferation, invasion and migration in vitro and in vivo. Therefore, we aimed to elucidate the mechanisms by which ERβ elicits its anti-cancer effects in TNBC. RNAseq analysis of ERβ-expressing MDA-MB-231 cells demonstrated that ERβ significantly downregulates NFκB signaling in the presence of E2. ChIPseq for ERβ in these cells revealed that ERβ primarily associated with estrogen response elements, but 12% of all ERβ binding sites were located at NFκB consensus motifs. Using an NFκB reporter construct and qPCR, ERβ was shown to block TNFα-mediated induction of NFκB signaling and NFκB target gene expression. RNAseq analysis of MDA-MB-231-ERβ cells treated with TNFα or E2+TNFα revealed substantial global inhibition of TNFα regulated genes in the presence of E2. ChIPseq for NFκB demonstrated that ERβ significantly alters NFκB’s cistrome whereby it can both diminish NFκB binding and redistribute NFκB throughout the genome. ChIPseq also demonstrated that ligand-mediated activation of ERβ significantly diminished an activating histone mark (H3K27Ac) at many of these NFκB target genes while enhancing a repressive mark (H3K27Me3). The addition of H3K27Me3 at these loci was shown to occur through the recruitment of the histone methyltransferase, EZH2. Drug-mediated blockade of EZH2 activity reversed suppression of NFκB target gene expression by ERβ. Knockdown of NFκB or Mutation of ERβ’s DNA binding domain rendered ERβ incapable of associating with DNA, recruiting EZH2, methylating NFκB target gene loci, repressing NFκB target gene expression and inhibiting proliferation. Interestingly, ERβ was shown to elicit more potent anti-cancer effects in TNBC cells expression a constitutively active form of NFκB. These finding suggest that a primary mechanism by which ERβ functions as a tumor suppressor is through inhibition of NFκB pathway activity. Our studies have also revealed that ERβ functions as a molecular switch for EZH2 and repurposes it for tumor suppressive activities, as EZH2 has previously been reported to enrich NFκB signaling in TNBC. These findings could address the paradox that high EZH2 expression is associated with worse TNBC patient outcomes, while high H3K27Me3 expression is associated with improved patient outcomes. Currently, a Mayo Clinic Breast Cancer SPORE prospective phase II clinical trial is underway to investigate the efficacy of estradiol for the treatment of metastatic ERβ+TNBC and to further evaluate the cross-talk between ERβ, EZH2 and NFκB signaling.

Inverse Agonist of Estrogen-Related Receptor Α Suppresses the Growth of Triple Negative Breast Cancer Cells Through ROS Generation and Interaction with Multiple Cell Signaling Pathways.

Activation of ERβ Hijacks the Splicing Machinery to Trigger R-loop Formation in Triple-Negative Breast Cancer

Inhibition Of Err Alpha Suppresses Epithelial Mesenchymal Transition Of Triple Negative Breast Cancer Cells By Directly Targeting Fibronectin

Estrogen-Related Receptor Alpha (Err Alpha) Inverse Agonist Xct-790 Induces Cell Death In Chemotherapeutic Resistant Cancer Cells

Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression

ATR inhibition is a promising radiosensitizing strategy for triple negative breast cancer.

Oestrogen-Related Receptor Alpha Inverse Agonist Xct-790 Arrests A549 Lung Cancer Cell Population Growth by Inducing Mitochondrial Reactive Oxygen Species Production

Data from ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Apatinib-induced NF-κB Inactivation Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin.

Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway

CCT020312 Inhibits Triple-Negative Breast Cancer Through PERK Pathway-Mediated G1 Phase Cell Cycle Arrest and Apoptosis

A novel cystathionine γ-lyase inhibitor, I194496, inhibits the growth and metastasis of human TNBC via downregulating multiple signaling pathways

Chlorotoxin Targets ERα/VASP Signaling Pathway to Combat Breast Cancer

Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer.

SUN-LB135 Estrogen Receptor Beta Inhibits NFkB Signaling to Inhibit Triple Negative Breast Cancer

A Specific RAGE-binding Peptide Inhibits Triple Negative Breast Cancer Growth Through Blocking of Erk1/2/NF-κB Pathway.

Abstract 5550: Crosstalk of estrogen receptor Β with tumor microenvironment signaling explains tumor suppressor actions in TNBC

Estrogen Receptor-Α36 is Involved in Icaritin Induced Growth Inhibition of Triple-Negative Breast Cancer Cells

Natural product preferentially targets redox and metabolic adaptations and aberrantly active STAT3 to inhibit breast tumor growth in vivo

Therapeutic Activity Of Dcc-2036, A Novel Tyrosine Kinase Inhibitor, Against Triple-Negative Breast Cancer Patient-Derived Xenografts By Targeting Axl/Met

Small-molecule RL71-triggered excessive autophagic cell death as a potential therapeutic strategy in triple-negative breast cancer